AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Golden State Wealth Management LLC

Golden State Wealth Management LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 400.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,176 shares of the company’s stock after purchasing an additional 3,341 shares during the period. Golden State Wealth Management LLC’s holdings in AstraZeneca were worth $307,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of AZN. Bessemer Group Inc. boosted its stake in shares of AstraZeneca by 5.8% in the first quarter. Bessemer Group Inc. now owns 121,851 shares of the company’s stock valued at $8,956,000 after buying an additional 6,664 shares in the last quarter. Spire Wealth Management boosted its position in AstraZeneca by 10.6% during the first quarter. Spire Wealth Management now owns 7,065 shares of the company’s stock worth $519,000 after purchasing an additional 679 shares in the last quarter. Golden State Equity Partners raised its holdings in shares of AstraZeneca by 11.1% in the first quarter. Golden State Equity Partners now owns 6,455 shares of the company’s stock worth $474,000 after acquiring an additional 646 shares during the last quarter. E&G Advisors LP acquired a new position in shares of AstraZeneca in the first quarter worth $218,000. Finally, Chapin Davis Inc. raised its holdings in shares of AstraZeneca by 20.0% in the first quarter. Chapin Davis Inc. now owns 3,873 shares of the company’s stock worth $285,000 after acquiring an additional 646 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

NASDAQ AZN opened at $69.85 on Friday. The stock has a market cap of $216.63 billion, a price-to-earnings ratio of 28.05, a price-to-earnings-growth ratio of 1.28 and a beta of 0.38. The business has a fifty day moving average of $70.59 and a 200-day moving average of $70.48. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same period in the prior year, the firm posted $2.06 earnings per share. The firm’s revenue was up 7.2% on a year-over-year basis. As a group, analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas initiated coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.